In the HDL proteome, IGHG3 was significantly altered between healthy individuals and individuals with MASLD without steatohepatitis and between individuals with MASLD without steatohepatitis and MASH [39]. Here, IGHG3 is linked to metabolic dysfunction-associated steatotic liver disease.